Methylation-mediated gene silencing as biomarkers of gastric cancer: A review

World Journal of Gastroenterology

Volumn 20, Issue 34, 2014, Pages 11991-12006

  Nakamura, Jun ^a   Tanaka, Tomokazu ^a   Kitajima, Yoshihiko ^a,b   Noshiro, Hirokazu ^a   Miyazaki, Kohji ^a  

^a SAGA UNIVERSITY   (Japan)

^b Miyaki gun   (Japan)

Author keywords

Biomarker; Drug sensitivity; Early detection; Gastric cancer; Methylation

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SECRETED FRIZZLED RELATED PROTEIN 1; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRASTUZUMAB; TUMOR MARKER; UVOMORULIN; ANTINEOPLASTIC AGENT;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CARCINOGENESIS; DNA METHYLATION; DRUG SENSITIVITY; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS INFECTION; GENE FREQUENCY; GENE SILENCING; HELICOBACTER INFECTION; HUMAN; MICROMETASTASIS; PROMOTER REGION; REVIEW; RISK ASSESSMENT; STOMACH CANCER; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; METABOLISM; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PREDICTIVE VALUE; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EARLY DETECTION OF CANCER; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84909580782     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i34.11991     Document Type: Review

References (189)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
2. Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012; 4: 156-169 [PMID: 22844547 DOI: 10.4251/wjgo.v4.i7.156]
3. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011; 11: 726-734 [PMID: 21941284 DOI: 10.1038/nrc3130]
4. Miyamoto K, Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 2005; 35: 293-301 [PMID: 15930038 DOI: 10.1093/jjco/hyi088]
5. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196: 261-282 [PMID: 3656447 DOI: 10.1016/0022-2836(87)90689-9]
6. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116 [PMID: 16491070 DOI: 10.1038/nrc1799]
7. Shames DS, Minna JD, Gazdar AF. DNA methylation in health, disease, and cancer. Curr Mol Med 2007; 7: 85-102 [PMID: 17311535 DOI: 10.2174/156652407779940413]
8. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-266 [PMID: 12671664 DOI: 10.1038/nrc1045]
9. Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, van Engeland M, Ting AH, Jair K, Yu W, Toyota M, Imai K, Ahuja N, Herman JG, Baylin SB. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007; 3: 1709-1723 [PMID: 17892325 DOI: 10.1371/journal.pgen.0030157]
10. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274 [PMID: 16959974 DOI: 10.1126/science.1133427]
11. Fang J, Zhu S, Xiao S, Shi Y, Jiang S, Zhou X, Qian L. Alterations of level of total genomic DNA methylation and pattern of c-myc, c-Ha-ras oncogene methylation in human gastric carcinogenesis. Chin Med J (Engl) 1996; 109: 787-791 [PMID: 9275356]
12. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Terashima M, Motoyama T, Meltzer SJ. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92: 569-573 [PMID: 10749913 DOI: 10.1093/jnci/92.7.569]
13. Tamura G, Sato K, Akiyama S, Tsuchiya T, Endoh Y, Usuba O, Kimura W, Nishizuka S, Motoyama T. Molecular characterization of undifferentiated-type gastric carcinoma. Lab Invest 2001; 81: 593-598 [PMID: 11304579 DOI: 10.1038/labinvest.3780268]
14. Ksiaa F, Ziadi S, Amara K, Korbi S, Trimeche M. Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma. Clin Chim Acta 2009; 404: 128-133 [PMID: 19336228 DOI: 10.1016/j.cca.2009.03.044]
15. Oshimo Y, Kuraoka K, Nakayama H, Kitadai Y, Yoshida K, Chayama K, Yasui W. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 2004; 112: 1003-1009 [PMID: 15386345 DOI: 10.1002/ijc.20521]
16. Nojima M, Suzuki H, Toyota M, Watanabe Y, Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K, Hirata K, Itoh F, Tokino T, Mori M, Imai K, Shinomura Y. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 2007; 26: 4699-4713 [PMID: 17297461 DOI: 10.1038/sj.onc.1210259]
17. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002; 82: 285-291 [PMID: 11896207 DOI: 10.1038/labinvest.3780422]
18. Sapari NS, Loh M, Vaithilingam A, Soong R. Clinical potential of DNA methylation in gastric cancer: a meta-analysis. PLoS One 2012; 7: e36275 [PMID: 22558417 DOI: 10.1371/journal.pone.0036275]
19. Kang GH, Lee S, Cho NY, Gandamihardja T, Long TI, Weisenberger DJ, Campan M, Laird PW. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 2008; 88: 161-170 [PMID: 18158559 DOI: 10.1038/labinvest.3700707]
20. Wang LJ, Jin HC, Wang X, Lam EK, Zhang JB, Liu X, Chan FK, Si JM, Sung JJ. ZIC1 is downregulated through promoter hypermethylation in gastric cancer. Biochem Biophys Res Commun 2009; 379: 959-963 [PMID: 19135984 DOI: 10.1016/j.bbrc.2008.12.180]
21. Shu XS, Geng H, Li L, Ying J, Ma C, Wang Y, Poon FF, Wang X, Ying Y, Yeo W, Srivastava G, Tsao SW, Yu J, Sung JJ, Huang S, Chan AT, Tao Q. The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors. PLoS One 2011; 6: e27346 [PMID: 22087297 DOI: 10.1371/journal.pone.0027346]
22. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK, Sung JJ. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009; 136: 640-651.e1 [PMID: 19084528 DOI: 10.1053/j.gastro.2008.10.050]
23. Jee CD, Kim MA, Jung EJ, Kim J, Kim WH. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur J Cancer 2009; 45: 1282-1293 [PMID: 19195878 DOI: 10.1016/j.ejca.2008.12.027]
24. Lu XX, Yu JL, Ying LS, Han J, Wang S, Yu QM, Wang XB, Fang XH, Ling ZQ. Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer 2012; 118: 5507-5517 [PMID: 22576578 DOI: 10.1002/cncr.27604]
25. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692 [PMID: 17320506 DOI: 10.1016/j.cell.2007.01.029]
26. Dong W, Tu S, Xie J, Sun P, Wu Y, Wang L. Frequent promoter hypermethylation and transcriptional downregulation of BTG4 gene in gastric cancer. Biochem Biophys Res Commun 2009; 387: 132-138 [PMID: 19576178 DOI: 10.1016/j.bbrc.2009.06.140]
27. Cheng YY, Yu J, Wong YP, Man EP, To KF, Jin VX, Li J, Tao Q, Sung JJ, Chan FK, Leung WK. Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer 2007; 97: 895-901 [PMID: 17848950]
28. Wani M, Afroze D, Makhdoomi M, Hamid I, Wani B, Bhat G, Wani R, Wani K. Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir valley. Asian Pac J Cancer Prev 2012; 13: 4177-4181 [PMID: 23098428 DOI: 10.7314/APJCP.2012.13.8.4177]
29. Yu J, Tao Q, Cheng YY, Lee KY, Ng SS, Cheung KF, Tian L, Rha SY, Neumann U, Röcken C, Ebert MP, Chan FK, Sung JJ. Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 2009; 115: 49-60 [PMID: 19051296 DOI: 10.1002/cncr.23989]
30. Joo JK, Kim SH, Kim HG, Kim DY, Ryu SY, Lee KH, Lee JH. CpG methylation of transcription factor 4 in gastric carcinoma. Ann Surg Oncol 2010; 17: 3344-3353 [PMID: 20585880 DOI: 10.1245/s10434-010-1131-z]
31. Wu CS, Lu YJ, Li HP, Hsueh C, Lu CY, Leu YW, Liu HP, Lin KH, Hui-Ming Huang T, Chang YS. Glutamate receptor, ionotropic, kainate 2 silencing by DNA hypermethylation possesses tumor suppressor function in gastric cancer. Int J Cancer 2010; 126: 2542-2552 [PMID: 19824040 DOI: 10.1002/ijc.24958]
32. Ben Ayed-Guerfali D, Benhaj K, Khabir A, Abid M, Bayrouti MI, Sellami-Boudawara T, Gargouri A, Mokdad-Gargouri R. Hypermethylation of tumor-related genes in Tunisian patients with gastric carcinoma: clinical and biological significance. J Surg Oncol 2011; 103: 687-694 [PMID: 21308683 DOI: 10.1002/jso.21875]
33. Hiraki M, Kitajima Y, Koga Y, Tanaka T, Nakamura J, Hashiguchi K, Noshiro H, Miyazaki K. Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients. Ann Surg Oncol 2011; 18: 3013-3019 [PMID: 21409489 DOI: 10.1245/s10434-011-1636-0]
34. Lu YJ, Wu CS, Li HP, Liu HP, Lu CY, Leu YW, Wang CS, Chen LC, Lin KH, Chang YS. Aberrant methylation impairs low density lipoprotein receptor-related protein 1B tumor suppressor function in gastric cancer. Genes Chromosomes Cancer 2010; 49: 412-424 [PMID: 20095042 DOI: 10.1002/gcc.20752]
35. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999; 24: 73-76 [PMID: 10098402 DOI: 10.1016/S0968-0004(98)01343-7]
36. Chan AO. E-cadherin in gastric cancer. World J Gastroenterol 2006; 12: 199-203 [PMID: 16482618]
37. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 2006; 12: 192-198 [PMID: 16482617]
38. Waki T, Tamura G, Tsuchiya T, Sato K, Nishizuka S, Motoyama T. Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol 2002; 161: 399-403 [PMID: 12163364 DOI: 10.1016/S0002-9440(10)64195-8]
39. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315-319 [PMID: 10888881 DOI: 10.1038/77083]
40. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 2001; 61: 7034-7038 [PMID: 11585730]
41. Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, Tommasi S, Pfeifer GP. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003; 18: 665-677 [PMID: 12647816]
42. To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, Ng EK, Chung SC, Sung JJ. Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 2002; 102: 623-628 [PMID: 12448005 DOI: 10.1002/ijc.10783]
43. Yao D, Shi J, Shi B, Wang N, Liu W, Zhang G, Ji M, Xu L, He N, Hou P. Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta 2012; 413: 787-794 [PMID: 22285775 DOI: 10.1016/j.cca.2012.01.013]
44. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315 [PMID: 6145023 DOI: 10.1016/S0140-6736(84)91816-6]
45. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325: 1132-1136 [PMID: 1891021 DOI: 10.1056/NEJM199110173251604]
46. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-1131 [PMID: 1891020 DOI: 10.1056/NEJM199110173251603]
47. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]
48. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12: 989-995 [PMID: 16467114 DOI: 10.1158/1078-0432.CCR-05-2096]
49. Kitajima Y, Ohtaka K, Mitsuno M, Tanaka M, Sato S, Nakafusa Y, Miyazaki K. Helicobacter pylori infection is an independent risk factor for Runx3 methylation in gastric cancer. Oncol Rep 2008; 19: 197-202 [PMID: 18097595]
50. Fukamachi H, Ito K, Ito Y. Runx3-/- gastric epithelial cells differentiate into intestinal type cells. Biochem Biophys Res Commun 2004; 321: 58-64 [PMID: 15358215 DOI: 10.1016/j.bbrc.2004.06.099]
51. Park SY, Yoo EJ, Cho NY, Kim N, Kang GH. Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. J Pathol 2009; 219: 410-416 [PMID: 19639607 DOI: 10.1002/path.2596]
52. Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M, Sugiyama T, Ushijima T. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 2009; 124: 2367-2374 [PMID: 19165869 DOI: 10.1002/ijc.24219]
53. Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S, Ichinose M, Sugimura T, Ushijima T, Saito D. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006; 15: 2317-2321 [PMID: 17119066 DOI: 10.1158/1055-9965.EPI-06-0436]
54. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, Ichinose M, Tatematsu M, Ushijima T. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010; 70: 1430-1440 [PMID: 20124475 DOI: 10.1158/0008-5472.CAN-09-2755]
55. Hur K, Niwa T, Toyoda T, Tsukamoto T, Tatematsu M, Yang HK, Ushijima T. Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. Carcinogenesis 2011; 32: 35-41 [PMID: 20980348 DOI: 10.1093/carcin/bgq219]
56. Qian X, Huang C, Cho CH, Hui WM, Rashid A, Chan AO. E-cadherin promoter hypermethylation induced by interleukin-1beta treatment or H. pylori infection in human gastric cancer cell lines. Cancer Lett 2008; 263: 107-113 [PMID: 18249489 DOI: 10.1016/j.canlet.2007.12.023]
57. Wang YQ, Li YM, Li X, Liu T, Liu XK, Zhang JQ, Guo JW, Guo LY, Qiao L. Hypermethylation of TGF-β1 gene promoter in gastric cancer. World J Gastroenterol 2013; 19: 5557-5564 [PMID: 24023501 DOI: 10.3748/wjg.v19.i33.5557]
58. Wang M, Furuta T, Takashima M, Futami H, Shirai N, Hanai H, Kaneko E. Relation between interleukin-1beta messenger RNA in gastric fundic mucosa and gastric juice pH in patients infected with Helicobacter pylori. J Gastroenterol 1999; 34 Suppl 11: 10-17 [PMID: 10616759]
59. Yamaoka Y, Kita M, Kodama T, Sawai N, Kashima K, Imanishi J. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 1997; 41: 442-451 [PMID: 9391240 DOI: 10.1136/gut.41.4.442]
60. Leung WK, Yu J, Ng EK, To KF, Ma PK, Lee TL, Go MY, Chung SC, Sung JJ. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. Cancer 2001; 91: 2294-2301 [PMID: 11413518]
61. Chan AO, Peng JZ, Lam SK, Lai KC, Yuen MF, Cheung HK, Kwong YL, Rashid A, Chan CK, Wong BC. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut 2006; 55: 463-468 [PMID: 16428266 DOI: 10.1136/gut.2005.077776]
62. Niwa T, Toyoda T, Tsukamoto T, Mori A, Tatematsu M, Ushijima T. Prevention of Helicobacter pylori-induced gastric cancers in gerbils by a DNA demethylating agent. Cancer Prev Res (Phila) 2013; 6: 263-270 [PMID: 23559452 DOI: 10.1158/1940-6207.CAPR-12-0369]
63. Niedobitek G, Agathanggelou A, Steven N, Young LS. Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells. Mol Pathol 2000; 53: 37-42 [PMID: 10884920 DOI: 10.1136/mp.53.1.37]
64. Epstein MA, Barr YM. Cultivation in vitro of human lymphoblasts from burkitt's malignant lymphoma. Lancet 1964; 1: 252-253 [PMID: 14090852]
65. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970; 228: 1056-1058 [PMID: 4320657 DOI: 10.1038/2281056a0]
66. Burke AP, Yen TS, Shekitka KM, Sobin LH. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol 1990; 3: 377-380 [PMID: 2163534]
67. Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E. Epstein-Barr virus in gastric carcinoma. Am J Pathol 1993; 143: 1250-1254 [PMID: 8238241]
68. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992; 140: 769-774 [PMID: 1314023]
69. Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, Ro JY. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 2002; 160: 787-794 [PMID: 11891177 DOI: 10.1016/S0002-9440(10)64901-2]
70. Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M, Hosokawa M, Shinomura Y, Imai K, Tokino T. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006; 106: 1467-1479 [PMID: 16518809 DOI: 10.1002/cncr.21789]
71. Chang MS, Uozaki H, Chong JM, Ushiku T, Sakuma K, Ishikawa S, Hino R, Barua RR, Iwasaki Y, Arai K, Fujii H, Nagai H, Fukayama M. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 2006; 12: 2995-3002 [PMID: 16707594 DOI: 10.1158/1078-0432.CCR-05-1601]
72. Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res 2012; 72: 3445-3450 [PMID: 22761333 DOI: 10.1158/0008-5472.CAN-11-3919]
73. Ushiku T, Chong JM, Uozaki H, Hino R, Chang MS, Sudo M, Rani BR, Sakuma K, Nagai H, Fukayama M. p73 gene promoter methylation in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 2007; 120: 60-66 [PMID: 17058198 DOI: 10.1002/ijc.22275]
74. Okada T, Nakamura M, Nishikawa J, Sakai K, Zhang Y, Saito M, Morishige A, Oga A, Sasaki K, Suehiro Y, Hinoda Y, Sakaida I. Identification of genes specifically methylated in Epstein-Barr virus-associated gastric carcinomas. Cancer Sci 2013; 104: 1309-1314 [PMID: 23829175 DOI: 10.1111/cas.12228]
75. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, Sakatani T, Takada K, Fukayama M. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 2009; 69: 2766-2774 [PMID: 19339266 DOI: 10.1158/0008-5472.CAN-08-3070]
76. Zhao J, Liang Q, Cheung KF, Kang W, Lung RW, Tong JH, To KF, Sung JJ, Yu J. Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. Cancer 2013; 119: 304-312 [PMID: 22833454 DOI: 10.1002/cncr.27724]
77. Matsusaka K, Kaneda A, Nagae G, Ushiku T, Kikuchi Y, Hino R, Uozaki H, Seto Y, Takada K, Aburatani H, Fukayama M. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res 2011; 71: 7187-7197 [PMID: 21990320 DOI: 10.1158/0008-5472.CAN-11-1349]
78. Garcia M, Jemal A. Global Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society, 2011
79. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983; 51: 2116-2120 [PMID: 6188527]
80. Abbaszadegan MR, Moaven O, Sima HR, Ghafarzadegan K, A'rabi A, Forghani MN, Raziee HR, Mashhadinejad A, Jafarzadeh M, Esmaili-Shandiz E, Dadkhah E. p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J Gastroenterol 2008; 14: 2055-2060 [PMID: 18395906 DOI: 10.3748/wjg.14.2055]
81. Kanyama Y, Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S, Nakao A. Detection of p16 promoter hypermethylation in serum of gastric cancer patients. Cancer Sci 2003; 94: 418-420 [PMID: 12824886 DOI: 10.1111/j.1349-7006.2003.tb01457.x]
82. Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum Pathol 2009; 40: 1534-1542 [PMID: 19695681 DOI: 10.1016/j.humpath.2009.01.029]
83. Zheng Y, Zhang Y, Huang X, Chen L. Analysis of the RUNX3 gene methylation in serum DNA from esophagus squamous cell carcinoma, gastric and colorectal adenocarcinoma patients. Hepatogastroenterology 2011; 58: 2007-2011 [PMID: 22234069 DOI: 10.5754/hge10016]
84. Sakakura C, Hamada T, Miyagawa K, Nishio M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E, Chiba T, Ito K, Ito Y. Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer Res 2009; 29: 2619-2625 [PMID: 19596937]
85. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol 2008; 14: 3074-3080 [PMID: 18494062 DOI: 10.3748/wjg.14.3074]
86. Hibi K, Goto T, Shirahata A, Saito M, Kigawa G, Nemoto H, Sanada Y. Detection of TFPI2 methylation in the serum of gastric cancer patients. Anticancer Res 2011; 31: 3835-3838 [PMID: 22110206]
87. Chan MW, Chu ES, To KF, Leung WK. Quantitative detection of methylated SOCS-1, a tumor suppressor gene, by a modified protocol of quantitative real time methylation-specific PCR using SYBR green and its use in early gastric cancer detection. Biotechnol Lett 2004; 26: 1289-1293 [PMID: 15483389]
88. Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, Chan FK, Sung JJ. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer 2005; 92: 2190-2194 [PMID: 15942635 DOI: 10.1038/sj.bjc.6602636]
89. Oishi Y, Watanabe Y, Yoshida Y, Sato Y, Hiraishi T, Oikawa R, Maehata T, Suzuki H, Toyota M, Niwa H, Suzuki M, Itoh F. Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer. Tumour Biol 2012; 33: 383-393 [PMID: 22161215 DOI: 10.1007/s13277-011-0278-y]
90. Watanabe Y, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K, Guo Y, Ahmed SS, Toyota M, Itoh F, Suk KT, Cho MY, Shen L, Jelinek J, Issa JP. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 2009; 136: 2149-2158 [PMID: 19375421 DOI: 10.1053/j.gastro.2009.02.085]
91. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242 [PMID: 10671934 DOI: 10.1046/j.1365-2168.2000.01360.x]
92. Broll R, Weschta M, Windhoevel U, Berndt S, Schwandner O, Roblick U, Schiedeck TH, Schimmelpenning H, Bruch HP, Duchrow M. Prognostic significance of free gastrointestinal tumor cells in peritoneal lavage detected by immunocytochemistry and polymerase chain reaction. Langenbecks Arch Surg 2001; 386: 285-292 [PMID: 11466571 DOI: 10.1007/s004230100209]
93. Lee CC, Lo SS, Wu CW, Shen KH, Li AF, Hsieh MC, Lui WY. Peritoneal recurrence of gastric adenocarcinoma after curative resection. Hepatogastroenterology 2003; 50: 1720-1722 [PMID: 14571826]
94. Yu QM, Wang XB, Luo J, Wang S, Fang XH, Yu JL, Ling ZQ. CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer. J Surg Oncol 2012; 106: 765-771 [PMID: 22514028 DOI: 10.1002/jso.23116]
95. Ikeda Y, Saku M, Kishihara F, Maehara Y. Effective followup for recurrence or a second primary cancer in patients with early gastric cancer. Br J Surg 2005; 92: 235-239 [PMID: 15609385 DOI: 10.1002/bjs.4758]
96. Doekhie FS, Mesker WE, van Krieken JH, Kok NF, Hartgrink HH, Kranenbarg EK, Putter H, Kuppen PJ, Tanke HJ, Tollenaar RA, van de Velde CJ. Clinical relevance of occult tumor cells in lymph nodes from gastric cancer patients. Am J Surg Pathol 2005; 29: 1135-1144 [PMID: 16096401 DOI: 10.1097/01.pas.0000160439.38770.cb]
97. Yonemura Y, Endo Y, Hayashi I, Kawamura T, Yun HY, Bandou E. Proliferative activity of micrometastases in the lymph nodes of patients with gastric cancer. Br J Surg 2007; 94: 731-736 [PMID: 17377930 DOI: 10.1002/bjs.5604]
98. Kim JH, Park JM, Jung CW, Park SS, Kim SJ, Mok YJ, Kim CS, Chae YS, Bae JW. The significances of lymph node micrometastasis and its correlation with E-cadherin expression in pT1-T3N0 gastric adenocarcinoma. J Surg Oncol 2008; 97: 125-130 [PMID: 18095267 DOI: 10.1002/jso.20937]
99. Kubota K, Nakanishi H, Hiki N, Shimizu N, Tsuji E, Yamaguchi H, Mafune K, Tange T, Tatematsu M, Kaminishi M. Quantitative detection of micrometastases in the lymph nodes of gastric cancer patients with real-time RT-PCR: a comparative study with immunohistochemistry. Int J Cancer 2003; 105: 136-143 [PMID: 12672044 DOI: 10.1002/ijc.11031]
100. Ikeda S, Funakoshi N, Usui S, Takiguchi N, Hiranuma S, Shibata T. Prognostic significance of gastric cancer metastasis in second-tier lymph nodes detected on reverse transcriptase-polymerase chain reaction and immunohistochemistry. Pathol Int 2008; 58: 45-50 [PMID: 18067640 DOI: 10.1111/j.1440-1827.2007.02187.x]
101. Arigami T, Natsugoe S, Uenosono Y, Yanagita S, Ehi K, Arima H, Mataki Y, Nakajo A, Ishigami S, Aikou T. Vascular endothelial growth factor-C and -D expression correlates with lymph node micrometastasis in pN0 early gastric cancer. J Surg Oncol 2009; 99: 148-153 [PMID: 19117016 DOI: 10.1002/jso.21228]
102. Yi Kim D, Kyoon Joo J, Kyu Park Y, Yeob Ryu S, Soo Kim H, Kyun Noh B, Hwa Lee K, Hyuk Lee J. E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis. J Surg Oncol 2007; 96: 429-435 [PMID: 17786966 DOI: 10.1002/jso.20732]
103. Hur K, Han TS, Jung EJ, Yu J, Lee HJ, Kim WH, Goel A, Yang HK. Up-regulated expression of sulfatases (SULF1 and SULF2) as prognostic and metastasis predictive markers in human gastric cancer. J Pathol 2012; 228: 88-98 [PMID: 22653794 DOI: 10.1002/path.4055]
104. Chang X, Li Z, Ma J, Deng P, Zhang S, Zhi Y, Chen J, Dai D. DNA methylation of NDRG2 in gastric cancer and its clinical significance. Dig Dis Sci 2013; 58: 715-723 [PMID: 23010743 DOI: 10.1007/s10620-012-2393-z]
105. Peng DF, Hu TL, Schneider BG, Chen Z, Xu ZK, El-Rifai W. Silencing of glutathione peroxidase 3 through DNA hypermethylation is associated with lymph node metastasis in gastric carcinomas. PLoS One 2012; 7: e46214 [PMID: 23071548 DOI: 10.1371/journal.pone.0046214]
106. Hiraki M, Kitajima Y, Sato S, Mitsuno M, Koga Y, Nakamura J, Hashiguchi K, Noshiro H, Miyazaki K. Aberrant gene methylation in the lymph nodes provides a possible marker for diagnosing micrometastasis in gastric cancer. Ann Surg Oncol 2010; 17: 1177-1186 [PMID: 19957042 DOI: 10.1245/s10434-009-0815-8]
107. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338 [PMID: 12724731 DOI: 10.1038/nrc1074]
108. Hashiguchi K, Kitajima Y, Kai K, Hiraki M, Nakamura J, Tokunaga O, Noshiro H, Miyazaki K. A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer. Int J Oncol 2010; 37: 257-264 [PMID: 20596652]
109. Ichikawa W. Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer 2006; 9: 145-155 [PMID: 16952032 DOI: 10.1007/s10120-006-0373-8]
110. Mitsuno M, Kitajima Y, Ide T, Ohtaka K, Tanaka M, Satoh S, Miyazaki K. Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients. J Gastroenterol 2007; 42: 866-873 [PMID: 18008030 DOI: 10.1007/s00535-007-2113-1]
111. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707 [PMID: 8259215 DOI: 10.1038/366704a0]
112. Iwadate Y, Mochizuki S, Fujimoto S, Namba H, Sakiyama S, Tagawa M, Yamaura A. Alteration of CDKN2/p16 in human astrocytic tumors is related with increased susceptibility to antimetabolite anticancer agents. Int J Oncol 2000; 17: 501-505 [PMID: 10938390]
113. Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, Yamada H, Kojima K, Sugihara K. Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 2008; 122: 603-608 [PMID: 17943730 DOI: 10.1002/ijc.23143]
114. van der Flier LG, van Gijn ME, Hatzis P, Kujala P, Haegebarth A, Stange DE, Begthel H, van den Born M, Guryev V, Oving I, van Es JH, Barker N, Peters PJ, van de Wetering M, Clevers H. Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell 2009; 136: 903-912 [PMID: 19269367 DOI: 10.1016/j.cell.2009.01.031]
115. Kwon OH, Park JL, Baek SJ, Noh SM, Song KS, Kim SY, Kim YS. Aberrant upregulation of ASCL2 by promoter demethylation promotes the growth and resistance to 5-fluorouracil of gastric cancer cells. Cancer Sci 2013; 104: 391-397 [PMID: 23181270 DOI: 10.1111/cas.12076]
116. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9: 2898-2903 [PMID: 12912934]
117. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11: 656-663 [PMID: 15701853]
118. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpré P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003; 9: 2912-2919 [PMID: 12912936]
119. Ilson DH. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 2007; 25: 3188-3190 [PMID: 17664464 DOI: 10.1200/JCO.2006.10.2210]
120. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279 [PMID: 14576837 DOI: 10.1038/sj.onc.1206933]
121. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001; 2: 483-490 [PMID: 11905724 DOI: 10.1016/S1470-2045(01)00454-5]
122. De Dosso S, Zanellato E, Nucifora M, Boldorini R, Sonzogni A, Biffi R, Fazio N, Bucci E, Beretta O, Crippa S, Saletti P, Frattini M. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2013; 72: 159-165 [PMID: 23645290 DOI: 10.1007/s00280-013-2181-2]
123. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS, Etienne-Grimaldi MC, Wei Q. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 2011; 17: 1632-1640 [PMID: 21278243 DOI: 10.1158/1078-0432.CCR-10-2169]
124. Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, Madhusudan S. Biomarkers of response to therapy in oesophago-gastric cancer. Gut 2009; 58: 127-143 [PMID: 19091831 DOI: 10.1136/gut.2008.155861]
125. Bataille F, Rümmele P, Dietmaier W, Gaag D, Klebl F, Reichle A, Wild P, Hofstädter F, Hartmann A. Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol 2003; 56: 286-292 [PMID: 14514923 DOI: 10.1136/mp.56.5.286]
126. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, Ooi CH, Lee J, Qin L, Wu J, Lee M, Rha SY, Huang D, Liem N, Yeoh KG, Yong WP, Teh BT, Tan P. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 2013; 62: 22-33 [PMID: 22535375 DOI: 10.1136/gutjnl-2011-301113]
127. Thériault BL, Shepherd TG, Mujoomdar ML, Nachtigal MW. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis 2007; 28: 1153-1162 [PMID: 17272306 DOI: 10.1093/carcin/bgm015]
128. Hamada S, Satoh K, Hirota M, Kimura K, Kanno A, Masamune A, Shimosegawa T. Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line. J Cell Physiol 2007; 213: 768-774 [PMID: 17516553 DOI: 10.1002/jcp.21148]
129. Barros R, Pereira B, Duluc I, Azevedo M, Mendes N, Camilo V, Jacobs RJ, Paulo P, Santos-Silva F, van Seuningen I, van den Brink GR, David L, Freund JN, Almeida R. Key elements of the BMP/SMAD pathway co-localize with CDX2 in intestinal metaplasia and regulate CDX2 expression in human gastric cell lines. J Pathol 2008; 215: 411-420 [PMID: 18498120 DOI: 10.1002/path.2369]
130. Lee PS, Teaberry VS, Bland AE, Huang Z, Whitaker RS, Baba T, Fujii S, Secord AA, Berchuck A, Murphy SK. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer 2010; 126: 1378-1389 [PMID: 19642140 DOI: 10.1002/ijc.24797]
131. Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics 2012; 7: 1225-1229 [PMID: 23069641 DOI: 10.4161/epi.22561]
132. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Peñas R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol 2005; 23: 9105-9112 [PMID: 16361617 DOI: 10.1200/JCO.2005.02.2905]
133. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12: 68-78 [PMID: 22193408 DOI: 10.1038/nrc3181]
134. Wang W, Figg WD. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biol Ther 2008; 7: 1004-1005 [PMID: 18720553 DOI: 10.4161/cbt.7.7.6409]
135. Bernal C, Vargas M, Ossandón F, Santibáñez E, Urrutia J, Luengo V, Zavala LF, Backhouse C, Palma M, Argandoña J, Aguayo F, Corvalán A. DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis. Biol Res 2008; 41: 303-315 [PMID: 19399343]
136. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10: 123-130 [PMID: 9484604 DOI: 10.1016/S0955-0674(98)80095-1]
137. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17: 1061-1070 [PMID: 10071301]
138. Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, Kojima H, Hiratsuka M, Arai K, Sairenji M, Fukushima N, Kimura H, Nakajima T. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer 2004; 7: 104-109 [PMID: 15224197 DOI: 10.1007/s10120-004-0278-3]
139. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T, Imai K. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003; 63: 8606-8613 [PMID: 14695171]
140. Yanokura M, Banno K, Kawaguchi M, Hirao N, Hirasawa A, Susumu N, Tsukazaki K, Aoki D. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncol Rep 2007; 17: 41-48 [PMID: 17143476]
141. Pillai RN, Brodie SA, Sica GL, Shaojin Y, Li G, Nickleach DC, Yuan L, Varma VA, Bonta D, Herman JG, Brock MV, Ribeiro MJ, Ramalingam SS, Owonikoko TK, Khuri FR, Brandes JC. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. Clin Cancer Res 2013; 19: 1603-1611 [PMID: 23386692 DOI: 10.1158/1078-0432.CCR-12-2995]
142. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000; 406: 430-435 [PMID: 10935642 DOI: 10.1038/35019108]
143. Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol 2006; 41: 133-139 [PMID: 16568372 DOI: 10.1007/s00535-005-1732-7]
144. Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Sergio CM, Gallego-Ortega D, Caldon CE, Ormandy CJ, Biankin AV, Gee JM, Nicholson RI, Print CG, Clark SJ, Musgrove EA. BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Mol Cancer Ther 2013; 12: 1874-1885 [PMID: 23861345 DOI: 10.1158/1535-7163.MCT-13-0012]
145. Gil EY, Jo UH, Jeong H, Whang YM, Woo OH, Cho KR, Seo JH, Kim A, Lee ES, Koh I, Kim YH, Park KH. Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. Int J Oncol 2012; 41: 611-620 [PMID: 22581300 DOI: 10.3892/ijo.2012.1470]
146. Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res 2012; 31: 6 [PMID: 22248469 DOI: 10.1186/1756-9966-31-6]
147. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP. Mechanism of action of camptothecin. Ann N Y Acad Sci 2000; 922: 1-10 [PMID: 11193884 DOI: 10.1111/j.1749-6632.2000.tb07020.x]
148. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13: 1841-1851 [PMID: 12453851 DOI: 10.1093/annonc/mdf337]
149. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, Shumway SD, Kurama T, Boothman DA, Miyamoto S. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 2000; 275: 9501-9509 [PMID: 10734098 DOI: 10.1074/jbc.275.13.9501]
150. Hiraki M, Kitajima Y, Nakafusa Y, Nakamura J, Hashiguchi K, Sumi K, Noshiro H, Miyazaki K. CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients. Oncol Rep 2010; 23: 191-197 [PMID: 19956881]
151. Shimizu S, Iida S, Ishiguro M, Uetake H, Ishikawa T, Takagi Y, Kobayashi H, Higuchi T, Enomoto M, Mogushi K, Mizushima H, Tanaka H, Sugihara K. Methylated BNIP3 gene in colorectal cancer prognosis. Oncol Lett 2010; 1: 865-872 [PMID: 22966396]
152. Gagnon JF, Bernard O, Villeneuve L, Têtu B, Guillemette C. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 2006; 12: 1850-1858 [PMID: 16551870 DOI: 10.1158/1078-0432.CCR-05-2130]
153. Xie FW, Peng Y, Chen X, Chen X, Li J, Wang W, Yu Z, Ouyang X. Relationship between the expression of CES2, UGT1A1, and GUSB in colorectal cancer tissues and aberrant methylation. Neoplasma 2014; 61: 99-109 [PMID: 24195516 DOI: 10.4149/neo-2014-014]
154. Miyaki Y, Suzuki K, Koizumi K, Kato T, Saito M, Kamiyama H, Maeda T, Shibata K, Shiya N, Konishi F. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer. Int J Oncol 2012; 40: 217-226 [PMID: 21901246 DOI: 10.3892/ijo.2011.1189]
155. Yamamoto F, Yamamoto M, Soto JL, Kojima E, Wang EN, Perucho M, Sekiya T, Yamanaka H. Notl-Msell methylation-sensitive amplied fragment length polymorhism for DNA methylation analysis of human cancers. Electrophoresis 2001; 22: 1946-1956 [PMID: 11465493]
156. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
157. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127 [PMID: 15324695 DOI: 10.1016/j.ccr.2004.06.022]
158. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402 [PMID: 17936563 DOI: 10.1016/j.ccr.2007.08.030]
159. Bediaga NG, Acha-Sagredo A, Guerra I, Viguri A, Albaina C, Ruiz Diaz I, Rezola R, Alberdi MJ, Dopazo J, Montaner D, Renobales M, Fernández AF, Field JK, Fraga MF, Liloglou T, de Pancorbo MM. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res 2010; 12: R77 [PMID: 20920229 DOI: 10.1186/bcr2721]
160. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, Borg A, Ringnér M. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010; 12: R36 [PMID: 20565864 DOI: 10.1186/bcr2590]
161. Lee JS, Fackler MJ, Lee JH, Choi C, Park MH, Yoon JH, Zhang Z, Sukumar S. Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biol Ther 2010; 9: 1017-1024 [PMID: 20505321 DOI: 10.4161/cbt.9.12.11804]
162. Terada K, Okochi-Takada E, Akashi-Tanaka S, Miyamoto K, Taniyama K, Tsuda H, Asada K, Kaminishi M, Ushijima T. Association between frequent CpG island methylation and HER2 amplification in human breast cancers. Carcinogenesis 2009; 30: 466-471 [PMID: 19168584 DOI: 10.1093/carcin/bgp021]
163. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976 [PMID: 21844504 DOI: 10.1200/JCO.2011.36.2236]
164. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30: 2119-2127 [PMID: 22565005 DOI: 10.1200/JCO.2011.39.9824]
165. Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA, Miles DW. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer 2011; 47: 2387-2395 [PMID: 21757334 DOI: 10.1016/j.ejca.2011.06.018]
166. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-2237 [PMID: 19307500 DOI: 10.1200/JCO.2008.20.0238]
167. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR, Scherer SJ. Biomarker results from the AVADO phase 3 trial of firstline bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 2013; 108: 1052-1060 [PMID: 23422754 DOI: 10.1038/bjc.2013.69]
168. Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012; 13: 724-733 [PMID: 22608783 DOI: 10.1016/S1470-2045(12)70231-0]
169. Kim JY, Hwang JH, Zhou W, Shin J, Noh SM, Song IS, Kim JY, Lee SH, Kim J. The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation. Epigenetics 2009; 4: 313-321 [PMID: 19633424 DOI: 10.4161/epi.4.5.9160]
170. Kim J, Hwang J, Jeong H, Song HJ, Shin J, Hur G, Park YW, Lee SH, Kim J. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells. Epigenetics 2012; 7: 191-200 [PMID: 22395469 DOI: 10.4161/epi.7.2.18973]
171. Vo QN, Geradts J, Boudreau DA, Bravo JC, Schneider BG. CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables. Hum Pathol 2002; 33: 1200-1204 [PMID: 12514789 DOI: 10.1053/hupa.2002.130108]
172. Wanajo A, Sasaki A, Nagasaki H, Shimada S, Otsubo T, Owaki S, Shimizu Y, Eishi Y, Kojima K, Nakajima Y, Kawano T, Yuasa Y, Akiyama Y. Methylation of the calcium channel-related gene, CACNA2D3, is frequent and a poor prognostic factor in gastric cancer. Gastroenterology 2008; 135: 580-590 [PMID: 18588891 DOI: 10.1053/j.gastro.2008.05.041]
173. Hu C, Lin F, Zhu G, Xue X, Ding Y, Zhao Z, Zhang L, Shen X. Abnormal hypermethylation of promoter region downregulates chemokine CXC ligand 14 expression in gastric cancer. Int J Oncol 2013; 43: 1487-1494 [PMID: 23982764 DOI: 10.3892/ijo.2013.2078]
174. Ling ZQ, Lv P, Lu XX, Yu JL, Han J, Ying LS, Zhu X, Zhu WY, Fang XH, Wang S, Wu YC. Circulating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer. PLoS One 2013; 8: e67195 [PMID: 23826230 DOI: 10.1371/journal.pone.0067195]
175. Kim TY, Jong HS, Jung Y, Kim TY, Kang GH, Bang YJ. DNA hypermethylation in gastric cancer. Aliment Pharmacol Ther 2004; 20 Suppl 1: 131-142 [PMID: 15298619 DOI: 10.1111/j.1365-2036.2004.01984.x]
176. Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, Silva R, Muretto P, Guilford P, Testa E, Mari D, Magnani M, Cascinu S. Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 2004; 10: 2784-2789 [PMID: 15102685 DOI: 10.1158/1078-0432.CCR-03-0320]
177. Park TJ, Han SU, Cho YK, Paik WK, Kim YB, Lim IK. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 2001; 92: 2760-2768 [PMID: 11753949]
178. Bae SI, Lee HS, Kim SH, Kim WH. Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers. Br J Cancer 2002; 86: 1888-1892 [PMID: 12085181 DOI: 10.1038/sj.bjc.6600372]
179. Kim SJ, Hwang JA, Ro JY, Lee YS, Chun KH. Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget 2013; 4: 1461-1471 [PMID: 23985992]
180. Tanaka T, Nakamura J, Kitajima Y, Kai K, Miyake S, Hiraki M, Ide T, Koga Y, Noshiro H. Loss of trefoil factor 1 is regulated by DNA methylation and is an independent predictive factor for poor survival in advanced gastric cancer. Int J Oncol 2013; 42: 894-902 [PMID: 23291975 DOI: 10.3892/ijo.2013.1759]
181. Yuasa Y, Nagasaki H, Oze I, Akiyama Y, Yoshida S, Shitara K, Ito S, Hosono S, Watanabe M, Ito H, Tanaka H, Kang D, Pan KF, You WC, Matsuo K. Insulin-like growth factor 2 hypomethylation of blood leukocyte DNA is associated with gastric cancer risk. Int J Cancer 2012; 131: 2596-2603 [PMID: 22447362 DOI: 10.1002/ijc.27554]
182. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008; 100: 1734-1738 [PMID: 19033568 DOI: 10.1093/jnci/djn359]
183. Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One 2011; 6: e23332 [PMID: 21829728 DOI: 10.1371/journal.pone.0023332]
184. Shigaki H, Baba Y, Watanabe M, Murata A, Iwagami S, Miyake K, Ishimoto T, Iwatsuki M, Baba H. LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastric Cancer 2013; 16: 480-487 [PMID: 23179365]
185. Park SY, Kook MC, Kim YW, Cho NY, Jung N, Kwon HJ, Kim TY, Kang GH. CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. Virchows Arch 2010; 457: 415-422 [PMID: 20737169 DOI: 10.1007/s00428-010-0962-0]
186. Chen HY, Zhu BH, Zhang CH, Yang DJ, Peng JJ, Chen JH, Liu FK, He YL. High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. Cancer Sci 2012; 103: 73-79 [PMID: 22017425 DOI: 10.1111/j.1349-7006.2011.02129.x]
187. Liu JB, Wu XM, Cai J, Zhang JY, Zhang JL, Zhou SH, Shi MX, Qiang FL. CpG island methylator phenotype and Helicobacter pylori infection associated with gastric cancer. World J Gastroenterol 2012; 18: 5129-5134 [PMID: 23049225 DOI: 10.3748/wjg.v18.i36.5129]
188. Yang Q, Wu K, Ji M, Jin W, He N, Shi B, Hou P. Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol 2013; 9: 1607-1616 [PMID: 23980508]
189. Tang H, Deng M, Tang Y, Xie X, Guo J, Kong Y, Ye F, Su Q, Xie X. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clin Cancer Res 2013; 19: 5602-5612 [PMID: 23995857 DOI: 10.1158/1078-0432.CCR-13-1326]